The latest research evidence confirms that FGF21 can improve metabolic status with anti-fibrotic effects and has the potential treatment for non-alcoholic steatohepatitis (NASH) (Harrison et al., 2021). Here, FGF21 is linked to metabolic dysfunction-associated steatohepatitis.